Arvinas, Inc. (ARVN)

Arvinas, Inc. (ARVN) stock has been impacted by several events including Q3 2025 earnings release with an EPS of -0.480 USD and revenue of $41.9 million, a decrease from the previous year. The Q2 2025 earnings release reported an EPS of -0.840 USD. An Annual General Meeting was held on June 25, 2025. As of February 5, 2026, the stock closed at $12.96, with a 52-week low of $5.90 and a high of $20.38, experiencing a -28.66% change over the past year. In September 2025, Arvinas refocused its strategy and optimized costs, projecting over $100 million in annual savings. Arvinas stock has received a consensus "buy" rating from analysts.

As a clinical-stage biotechnology company, the demand for Arvinas, Inc.'s products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by unmet medical needs, clinical trial progress, regulatory approvals, and market adoption of its therapeutic candidates.

Arvinas, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing therapies that degrade disease-causing proteins. The company operates in the Healthcare sector, specifically in Biotechnology & Medical Research and Pharmaceuticals & Medical Research. Arvinas leverages its PROTAC® Discovery Engine platform to engineer targeted protein degraders. Its major product candidates include Vepdegestrant (ARV-471) for breast cancer, ARV-766 and Bavdegalutamide for prostate cancer, ARV-102 for neurodegenerative disorders, ARV-393 targeting the BCL6 protein, and ARV-806, a PROTAC KRAS G12D degrader.

Arvinas, Inc. is headquartered in New Haven, Connecticut, USA, with expanded facilities at Yale's Science Park. While its primary operations are in New Haven, collaborations with companies like Pfizer suggest a broader global reach for therapy development and commercialization.

Arvinas, Inc.'s brand reputation is shaped by its pioneering work in targeted protein degradation and clinical advancements using its PROTAC® technology. While analysts maintain a consensus "buy" rating, scrutiny exists regarding its valuation and financial performance, as reflected in news headlines. The company's strategic refocus and cost-cutting measures in September 2025 aim to improve its financial standing and operational efficiency.

Arvinas, Inc.'s ownership is primarily held by institutional investors, who hold approximately 75.47% of the outstanding shares, including Vanguard Group Inc., BlackRock, Inc., and Pfizer Inc. Corporate insiders account for 24.53% of the shares, with Timothy M. Shannon being the largest individual insider. Retail investors hold a negligible percentage of the float.